SATB1 and acute myeloid leukemia: We presented data confirming that SATB1-AS1 expression in AML patients was enhanced relative to that observed in normal controls, and that SATB1-AS1 has the potency to reduce the chemosensitivity of AML both in vitro and in vivo.